AVXL
Anavex Life Sciences Corp.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Strong sell
-68/100
Last price
1.57
▼ 0.07 (4.52%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
1.57
Prev close
1.65
Day high
1.71
Day low
1.56
Volume
1.44M
Market cap
$148.31M
P/E (TTM)
—
52W range
1.56 – 10.10
Day trading desk
Gap from prior close
-4.52%
Prior close 1.64
VWAP
—
—
Relative volume
0.00×
Quiet session
Session range
—
1.57 – 1.57
Position in range
—
—
ATR (14D)
0.15
9.44% of price
Prior day high
1.82
PDH
Prior day low
1.63
PDL
Bid / ask spread
—
Quote not published
Session volume
—
Avg 954.54K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-32.20%
-34.2%
1M
-44.06%
-45.2%
3M
-40.74%
-45.3%
6M
-48.05%
-66.2%
YTD
-55.06%
-69.3%
1Y
-83.94%
-100.4%
3Y
-75.57%
-157.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on AVXL open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
1.58M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 11, 25 | MISSLING CHRISTOPHER U Chief Executive Officer |
CONVERSION | 187.50K | $945.00K | Direct |
| Jun 5, 25 | THOMAS STEFFEN PHD Director |
CONVERSION | 50.00K | $88.00K | Direct |
| Mar 24, 25 | MISSLING CHRISTOPHER U Chief Executive Officer |
CONVERSION | 500.00K | $460.00K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
MISSLING CHRISTOPHER U |
Chief Executive Officer | 1.51M | Conversion of Exercise of derivative security |
THOMAS STEFFEN PHD |
Director | 43.65K | Conversion of Exercise of derivative security |
Fundamentals
Market cap$148.31M
Enterprise value$29.99M
Revenue (TTM)—
Gross profit—
EBITDA—
Net income$-13.02M
EPS (TTM)$-0.14
Free cash flow$-27.06M
Total cash$118.33M
Total debt$0
Book value / share$1.21
Shares outstanding92.70M
Float89.81M
Short % of float15.73%
Dividend yield0.00%
Beta (5Y)1.17
Valuation & profitability ratios
Trailing P/E—
Forward P/E-2.91
PEG ratio—
Price / sales—
Price / book1.32
EV / revenue—
EV / EBITDA—
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-12.80%
Return on assets-9.70%
Debt / equity—
Current ratio15.62
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $37.59M | $41.84M | $43.72M | $37.92M | -10.1% |
| Selling, general & admin | $13.82M | $11.04M | $12.05M | $13.07M | +25.2% |
| Total operating expense | $51.37M | $52.80M | $55.74M | $50.99M | -2.7% |
| Operating income | -$51.37M | -$52.80M | -$55.74M | -$50.99M | +2.7% |
| Net interest income | $4.68M | $7.32M | $5.55M | $947.00K | -36.1% |
| Pre-tax income | -$46.38M | -$43.00M | -$47.51M | -$47.62M | -7.8% |
| Tax provision | — | $0 | $7.00K | $358.00K | — |
| Net income | -$46.38M | -$43.00M | -$47.51M | -$47.98M | -7.8% |
| Net income to common | -$46.38M | -$43.00M | -$47.51M | -$47.98M | -7.8% |
| Basic EPS | -0.54 | -0.52 | -0.60 | -0.62 | -3.8% |
| Diluted EPS | -0.54 | -0.52 | -0.60 | -0.62 | -3.8% |
| EBIT | -$46.38M | -$43.00M | -$46.54M | -$47.62M | -7.8% |
| EBITDA | -$46.38M | -$43.00M | -$46.54M | -$47.62M | -7.8% |
| Basic shares | 85.29M | 83.47M | 79.79M | 76.91M | +2.2% |
| Diluted shares | 85.29M | 83.47M | 79.79M | 76.91M | +2.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $102.58M | $132.19M | $151.02M | $149.16M | -22.4% |
| Cash & short-term investments | $102.58M | $132.19M | $151.02M | $149.16M | -22.4% |
| Total current assets | $103.81M | $135.57M | $154.39M | $152.71M | -23.4% |
| Total assets | $103.81M | $135.57M | $154.39M | $152.71M | -23.4% |
| Total current liabilities | $8.95M | $15.30M | $12.53M | $10.21M | -41.5% |
| Total liabilities | $8.95M | $15.30M | $12.53M | $10.21M | -41.5% |
| Retained earnings | -$382.45M | -$336.07M | -$293.07M | -$245.56M | -13.8% |
| Shareholder equity | $94.87M | $120.26M | $141.85M | $142.49M | -21.1% |
| Working capital | $94.87M | $120.26M | $141.85M | $142.49M | -21.1% |
| Net tangible assets | $94.87M | $120.26M | $141.85M | $142.49M | -21.1% |
| Shares issued | 86.67M | 84.80M | 82.07M | 77.94M | +2.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$46.38M | -$43.00M | -$47.51M | -$47.98M | -7.8% |
| Stock-based compensation | $11.55M | $9.44M | $16.37M | $18.38M | +22.4% |
| Change in working capital | -$4.22M | $2.75M | $2.50M | $5.36M | -253.2% |
| Operating cash flow | -$39.04M | -$30.81M | -$27.79M | -$24.24M | -26.7% |
| Financing cash flow | $9.43M | $11.97M | $29.65M | $21.29M | -21.2% |
| Free cash flow | -$39.04M | -$30.81M | -$27.79M | -$24.24M | -26.7% |
| End cash position | $102.58M | $132.19M | $151.02M | $149.16M | -22.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | -$4.71M | — | $4.66M | $7.29M | $9.96M | $9.89M | — |
| Selling, general & admin | -$2.03M | $2.29M | $2.13M | $3.55M | $4.50M | — | -188.7% |
| Total operating expense | -$6.77M | $6.46M | $6.78M | $11.48M | $14.31M | — | -204.9% |
| Operating income | $6.77M | -$6.46M | -$6.78M | -$11.48M | -$14.31M | — | +204.9% |
| Net interest income | $1.07M | $1.06M | $1.08M | $999.00K | $1.07M | — | +1.0% |
| Pre-tax income | $7.82M | -$5.34M | -$5.66M | -$9.83M | -$13.24M | — | +246.6% |
| Tax provision | $0 | $0 | $18.00K | — | $0 | $0 | — |
| Net income | $7.82M | -$5.34M | -$5.68M | -$9.83M | -$13.24M | — | +246.6% |
| Net income to common | $7.82M | -$5.34M | -$5.68M | -$9.83M | -$13.24M | — | +246.6% |
| Basic EPS | 0.08 | -0.06 | -0.06 | -0.11 | -0.16 | — | +233.3% |
| Diluted EPS | 0.08 | -0.06 | -0.06 | -0.11 | -0.16 | — | +233.3% |
| EBIT | $6.77M | -$6.46M | -$6.78M | -$6.49M | -$14.31M | — | +204.9% |
| EBITDA | $6.77M | -$6.46M | -$6.78M | -$6.49M | -$14.31M | — | +204.9% |
| Basic shares | 92.70M | 92.68M | 89.03M | 85.89M | 85.38M | — | +0.0% |
| Diluted shares | 92.90M | 92.68M | 89.03M | 85.89M | 85.38M | — | +0.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $118.33M | $127.42M | $131.75M | $102.58M | $101.16M | -7.1% |
| Cash & short-term investments | $118.33M | $127.42M | $131.75M | $102.58M | $101.16M | -7.1% |
| Total current assets | $120.14M | $128.77M | $132.99M | $103.81M | $102.43M | -6.7% |
| Total assets | $120.14M | $128.77M | $132.99M | $103.81M | $102.43M | -6.7% |
| Total current liabilities | $7.69M | $7.06M | $6.37M | $8.95M | $11.47M | +9.0% |
| Total liabilities | $7.69M | $7.06M | $6.37M | $8.95M | $11.47M | +9.0% |
| Retained earnings | -$385.64M | -$393.47M | -$388.13M | -$382.45M | -$372.62M | +2.0% |
| Shareholder equity | $112.45M | $121.71M | $126.62M | $94.87M | $90.96M | -7.6% |
| Working capital | $112.45M | $121.71M | $126.62M | $94.87M | $90.96M | -7.6% |
| Net tangible assets | $112.45M | $121.71M | $126.62M | $94.87M | $90.96M | -7.6% |
| Shares issued | 92.70M | 92.70M | 92.67M | 86.67M | 85.41M | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $7.82M | -$5.34M | -$5.68M | -$9.83M | -$13.24M | +246.6% |
| Stock-based compensation | -$17.08M | $314.00K | $1.11M | $3.72M | $4.32M | -5,540.8% |
| Change in working capital | $164.00K | $584.00K | -$2.58M | -$2.50M | -$3.54M | -71.9% |
| Operating cash flow | -$9.10M | -$4.44M | -$7.15M | -$8.60M | -$12.46M | -104.9% |
| Financing cash flow | $0 | $113.00K | $36.32M | $10.02M | -$2.14M | -100.0% |
| Free cash flow | -$9.10M | -$4.44M | -$7.15M | -$8.60M | -$12.46M | -104.9% |
| End cash position | $118.33M | $127.42M | $131.75M | $102.58M | $101.16M | -7.1% |
Options analytics
Put / call volume
1.35
Put-heavy session
Put / call open interest
0.25
Positioning, not flow
Max pain
1.00
-37.5% from spot
ATM implied vol
50.0%
Nearest strike to spot
Skew (10% OTM)
+237.5%
Puts bid over calls
Call volume
75
Contracts, this expiry
Put volume
101
Contracts, this expiry
Heaviest call OI
7.00
4 contracts
Heaviest put OI
1.00
1 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.08 | 0.08 | +200.0% |
| Mar 2026 | -0.07 | -0.06 | +14.3% |
| Dec 2025 | -0.11 | -0.06 | +45.5% |
| Sep 2025 | -0.15 | -0.11 | +26.7% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | — | — | $0 | — |
| Next year | — | — | $0 | — |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy0 / 1
Hold0
Sell / Strong sell0 / 0
Held by insiders1.71%
Held by institutions40.49%
Institutions holding232
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
2.08
-24.32% from price
SMA 20
2.29
-30.26% from price
SMA 50
2.77
-42.21% from price
SMA 100
2.70
-41.80% from price
SMA 200
3.33
-51.88% from price
EMA 12
2.06
-23.68% from price
EMA 26
2.34
-33.00% from price
EMA 50
2.56
-38.60% from price
RSI (14)
18.5
Oversold
MACD (12,26,9)
-0.29
Hist -0.07
ATR (14)
0.15
9.27% of price
Realised vol 30D
78.9%
Annualised
Bollinger upper
2.93
20, 2σ
Bollinger lower
1.66
20, 2σ
50 / 200 cross
Death
2.77 vs 3.33
Trend bias
Below 200
-51.88%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.66
More volatile than market
Correlation to SPY
0.24
Largely independent
Realised vol 30D
78.9%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-83.8%
Peak to trough
Max drawdown 5Y
-93.1%
Peak to trough
ATR 14
0.15
9.27% of price
Beta (reported)
1.17
5Y monthly, from filing
Short interest
Shares short
14.33M
Prior 14.11M
Change vs prior
+1.6%
Shorts adding
% of float
15.73%
Elevated
% of shares out
15.46%
Against total outstanding
Days to cover
20.0
Crowded exit
Float
89.81M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 31, 26 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Mar 26, 26 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Mar 23, 26 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Feb 10, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Feb 9, 26 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Jan 6, 26 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Dec 19, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Dec 19, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Dec 15, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Nov 28, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 26, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Nov 19, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split1:4
Split dateOct 7, 2015
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-28
Proxy Statements
DFAN14A · 2026-09-21
Proxy Statements
DFAN14A · 2026-09-18
Proxy Statements
DFAN14A · 2026-09-17
Proxy Statements
DEFA14A · 2026-09-15
Proxy Statements
DEFA14A · 2026-09-14
Proxy Statements
DFAN14A · 2026-09-10
Corporate Changes & Voting Matters
8-K · 2026-09-09
Headlines
Anavex Life Sciences Shareholders Elect All Six Board Nominees
MT Newswires · 13d ago
Anavex Stockholders Elect All of the Company’s Director Nominees at 2026 Annual Meeting
GlobeNewswire · 13d ago
PVG Asset Management Announces Plan for First 100 Days at Anavex Life Sciences
GlobeNewswire · 19d ago
Glass Lewis Recommends Anavex Stockholders Vote the GOLD Universal Proxy Card, Citing “Functionally Inert Stewardship” in Support of PVG Asset Management’s Call for Change
GlobeNewswire · 20d ago
PVG Asset Management Believes ISS Acknowledges Anavex’s Repeated Missteps, Failed Board Oversight, Lack of Director Stock Ownership, and AVXL Stock Price Underperformance
GlobeNewswire · 22d ago
Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote “FOR” All Six of Anavex’s Highly Qualified Director Nominees
GlobeNewswire · 23d ago
PVG Asset Management to Host Investor Call Regarding Anavex Life Sciences Proxy Campaign
GlobeNewswire · 27d ago
PVG Asset Management Issues Important Information About Anavex Life Sciences (AVXL)
GlobeNewswire · 28d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.